Inflazome

Inflazome is developing first in class, orally available drugs to address clinical unmet needs by targeting activation of the inflammasome.

The inflammasome is associated with harmful inflammation in a broad range of serious medical conditions including Alzheimer’s, Parkinson’s, inflammatory bowel disease, gout, osteoarthritis, liver, kidney and cardiovascular diseases. The company has proprietary new chemical entities that inhibit inflammasome-driven release of pro-inflammatory cytokines that exacerbate inflammation. In addition, they block innate immune cell pyroptosis (uncontrolled cell death), a process that leads to chronic inflammation. Inflazome was sold to Roche in 2020 for EUR380m upfront payment and undisclosed milestone payments.